Pfizer is taking Johnson & Johnson to court. Photo: Richard Drew / AP

Pfizer is suing Johnson & Johnson, alleging Johnson & Johnson crafted exclusive contracts with health insurers and health care providers to keep its autoimmune drug Remicade as a sole treatment option even though Pfizer came out with a cheaper biosimilar version, called Inflectra, this past November. The lawsuit says "consumers suffer in the form of artificially inflated prices."

Why it matters: When blockbuster drugs like Remicade lose patent protection or face competition from cheaper alternatives, drug companies face the prospect of losing billions of dollars in sales. This lawsuit between two of the largest U.S.-based pharmaceutical firms is yet another example of the extent companies will go to litigate or protect lucrative drugs.

Go deeper

Miriam Kramer, author of Space
9 mins ago - Science

The next environmental crisis could be in space

Illustration: Aïda Amer/Axios

An unexpected frontier is facing calls for new environmental regulations and cleanup: outer space.

Why it matters: Space junk clutters up orbits and poses an urgent threat to weather, security, communications and other satellites. Long-term, you can’t live or work in space if trash is literally slamming into you.

38 mins ago - Health

Axios-Ipsos poll: Trump's sickness makes him harder to trust

Data: Axios/Ipsos poll; Note: ±3.3% margin of error; Chart: Axios Visuals

Large shares of women, seniors and independents now say they're less likely to trust President Trump for accurate information about COVID-19 since he caught it himself, according to the latest installment of the Axios/Ipsos Coronavirus Index.

The big picture: Week 28 of our national survey has most Americans rejecting ideas that Trump has floated around hydroxychloriquine as a virus treatment, how herd immunity works or any imminent availability of a vaccine.

NY Post story goes massive on social media despite crackdowns

Data: NewsWhip; Chart: Naema Ahmed/Axios

Facebook and Twitter's frantic attempts to stop the spread of the New York Post's Hunter Biden story didn't prevent the article from becoming the top story about the election on those platforms last week, according to data from NewsWhip.

Why it matters: The data shows that even swift, aggressive content suppression may not be swift or aggressive enough to keep down a story with as much White House backing and partisan fuel as this one.